TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03924622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex
Description: Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex
Description: Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiCell
Description: LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
Study: NCT01466608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration of rosuvastatin 20 mg once daily for 21 days.
Study: NCT02962700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: muscle microdialysis
Description: Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle microdialysis
Description: Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
Study: NCT01064440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose VM202
Description: Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose VM202
Description: Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
Study: NCT03585660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic MRI
Description: Participants will be scanned using a standard clinical prostate MRI protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Prostate Biopsy
Description: Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Risk Map DSS tool
Description: The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
Study: NCT04588246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo salvage SRS
Study: NCT00307502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT05378230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)
Description: All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains.
Study: NCT04588246

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo salvage SRS
Study: NCT00790751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 30 minutes orally prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity
Study: NCT04588246

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo HA-WBRT
Study: NCT03995147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
Study: NCT03851445

Intervention type: DRUG
Group type: OTHER
Intervention: Screening Platform
Description: The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Study: NCT04002141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 1 tablet oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 5mg oral daily
Study: NCT01290458

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant vitamins
Description: Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Description: Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
Study: NCT01028989

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Reduced Glycemic Load Diet
Description: 36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard Diet
Description: 25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories
Study: NCT03493555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Navigator for PrEP
Description: Peer health systems navigator to improve adherence to PrEP
Study: NCT01489540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser Doppler imager (Moor)
Description: The laser Doppler imager measures the blood flow of the skin/burn
Study: NCT02759757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A micropore tape will be used as placebo
Study: NCT03992053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sacroiliac joint injection
Description: Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sacroiliac joint injection
Description: Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
Study: NCT00790751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity
Study: NCT02648204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study: NCT01418144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block
Description: Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TAP block
Description: Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
Study: NCT01533792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra/subgingival scaling using periodontal curette scraping
Description: The experimental group received supra and subgingival therapy with periodontal curettes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra/subgingival scaling using periodontal curette scraping
Description: The experimental group received supra and subgingival therapy with periodontal curettes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra and subgingival scaling
Description: The experimental group received supra and subgingival scaling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra and subgingival scaling
Description: The experimental group received supra and subgingival scaling.
Study: NCT03192176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fezolinetant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule
Study: NCT01827137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: optional post-ASCT therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: optional post-ASCT therapy
Study: NCT03800095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Study: NCT02893917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO
Study: NCT00674479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424
Description: Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
Study: NCT04179552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAAG-OA
Description: Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
Study: NCT03001557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 2.5 mg
Description: Lemborexant 2.5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: Lemborexant 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Lemborexant 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Lemborexant 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 15 mg
Description: Lemborexant 5 mg and 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets
Study: NCT00466232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
Study: NCT00127634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 months, up to 36 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable Insulin
Description: patient specific dose, injectable, before meals, 24 months, up to 36 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, as needed, 24 months up to 36 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient specific dose, injectable, as needed, 24 months up to 36 months
Study: NCT02655328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine sample
Description: urine sample
Study: NCT02855203

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiosurgery (SABR)
Description: 18-20Gy in 1 fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
Study: NCT02646826

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are treated with Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 1
Description: Subjects are treated with the first dose level of Paxerol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 2
Description: Subjects are treated with the second dose level of Paxerol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 3
Description: Subjects are treated with the third dose level of Paxerol
Study: NCT01814774

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study: NCT02866136

Intervention type: DRUG
Group type: OTHER
Intervention: VP16, carboplatin
Description: Systemic treatment : Intravenous injections, 2 cycles (21 days)

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: intraarterial injections, 3 to 6 cycles (1 month)
Study: NCT04668469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal protective Measures
Description: evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: personal protective Measures
Description: evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
Study: NCT02763059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
Study: NCT02866136

Intervention type: DRUG
Group type: OTHER
Intervention: VP16, carboplatin, vincristin
Description: Systemic treatment : Intravenous injections, 6 cycles (21 days)

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin + laser day 1 (chemothermotherapy)
Description: Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
Study: NCT02763059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receives 1 hour before surgery placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1000 mg
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Study: NCT02866136

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser (local treatment)

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser (local treatment)
Study: NCT02763059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1000 mg
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 1000 mg
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Study: NCT02529917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp powder
Description: Hemp powder supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Powder
Description: Soy powder supplement
Study: NCT03213340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catechin Cohort 1
Description: - 4 capsules taken with water 1 hour prior to meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curcuminoid Cohort 2
Description: - 2 capsules taken with water 1 hour prior to meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavonoid Cohort 3
Description: - \~ 1 oz. serving consumed 30 minutes before meal